Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/19/2026, 12:00:00 AM
Announced positive topline results from the Phase 3 trial of retatrutide for type 2 diabetes, showing significant reductions in both blood sugar and weight.
Korean Translation
제2형 당뇨병 치료제 레타트루타이드(retatrutide)의 3상 임상시험에서 혈당과 체중 모두에서 유의미한 감소를 보인 긍정적인 탑라인 결과를 발표함.
Related Recent Events
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-11. Analysts forecast revenue between $600M-$625M and adjusted EBITDA of $35M-$55M. Low importance is estimated as the market typically anticipates scheduled earnings results, which is forecasted.
5/11/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
First quarter 2026 earnings results and conference call scheduled.
5/5/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
Q1 2026 earnings release on May 5, 2026, with low importance estimated as the date is unconfirmed, expected.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM